VIP - alloSCT patients
The population is composed of hematologic malignancy patients receiving an allogeneic hematopoietic stem cell transplant (alloSCT), aged 18 years and older, who intend to receive the COVID-19 vaccine or have received the COVID-19 vaccine at any time in the past.
The population is composed of hematologic malignancy patients receiving an allogeneic hematopoietic stem cell transplant (alloSCT), aged 18 years and older, who intend to receive the COVID-19 vaccine or have received the COVID-19 vaccine at any time in the past.
-
Minimum age
-
18
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
Edmonton, Montreal, Ottawa, Toronto
-
Ethnic Origin
-
-
Health Status
-
Participants are diagnosed with hematologic malignancy. Patients with Chronic Grade II-IV graft-versus-host-disease may only be included if they are elligible for vaccination.
Participants are excluded if they have chronic myelogenous leukemia, myeloproliferative neoplasm not on cytoreductive therapy, or any absolute contraindications to the COVID-19 vaccine.
-
Other Criteria
-
Participants are included if it has been at least 3 months since they have received an allogeneic hematopoietic stem cell transplant from the time of enrollment.
Participants are excluded if they received an autologous stem cell transplantation (autoSCT) or allogeneic hematopoietic stem cell transplantation (alloSCT) treatment for non-hematologic malignancy diseases.
-
Sources of recruitment
-
-
Specific Population
-
-
Supplementary Information
-
Participants are recruited in hematology clinics from one of twelve participating hospitals around Canada.
-
Number of Participants
-
216
-
Number of Participants with Biological Samples
-
216